Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Dyno Therapeutics

Dyno Therapeutics

Dyno Therapeutics is a company based in Cambridge, Massachusetts applying artificial intelligence to gene therapy, focused on adeno-associated virus capsid engineering.

Dyno Therapeutics is a VC-backed biotech startup based in Cambridge, Massachusetts. The company develops DNA technologies and machine learning to engineer adeno-associated Virus (AAV) capsids for the effective delivery of gene therapies.

Founded in 2018 by a team of scientists that includes George Church, Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT).

Dyno Therapeutics' AI-powered approach to gene therapy uses machine learning and quantitative high-throughput in vivo experimentation. They aim to invent new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

The company emerged from stealth mode on May 11th, 2020, announcing its proprietary platform, CapsidMap. Dyno CEO and Co-Founder Eric Kelsic stated

At Dyno, we see a vast opportunity to expand the treatment landscape for gene therapies. The success of gene therapy relies on the ability of vectors to safely and precisely deliver a gene to the intended target cells and tissues. Our approach addresses the major limitations of naturally occurring AAV vectors and creates optimized, disease-specific vectors for gene therapies with great curative potential. Our portfolio of R&D programs and newly-announced collaborations with leading gene therapy developers reflect the applicability of our AI-powered approach to improve treatments for patients and expand the number of treatable diseases with gene therapies.

Dyno Therapeutics has announced partnerships with gene therapy companies Novartis and Sarepta Therapeutics.

Funding
Seed round

Dyno Therapeutics raised $9M in Seed round funding on May 11, 2020. Lead investors were Polaris Partners & CRV.

Timeline

May 6, 2021
Dyno Therapeutics raises a $100,000,000 series A round.
May 2020
Dyno Therapeutics raises a $9,000,000 seed round from Charles River Ventures and Polaris Partners.

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

Jobs with Dyno Therapeutics

Web

News

Title
Author
Date
Publisher
Description
Alex Keown
May 6, 2021
BioSpace
Since emerging from stealth mode in 2020 Dyno Therapeutics has been busy advancing its gene therapy platform. This morning, the company bolsters its research with $100 million raised in a Series A financing round.
FinSMEs
May 6, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
BioSpace
May 6, 2021
BioSpace
Dyno Therapeutics, Inc. , a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a $100 million Series A financing led by Andreessen Horowitz, with participation from a select syndicate of new investors
Amirah Al Idrus
May 6, 2021
FierceBiotech
Dyno Therapeutics emerged last year with a modest seed round and Big Pharma partnerships to fuel its work designing new and improved viral vectors to deliver gene therapy. Now, the company is kicking it up a notch with a $100 million financing to expand its platform into new tissues, build its team and ink more partnerships.
BioSpace
April 26, 2021
BioSpace
Dyno Therapeutics, a biotech company applying artificial intelligence (AI) to gene therapy, today announced the expansion of the company's Scientific Advisory Board (SAB) with the addition of Debora Marks, Ph.D., of Harvard Medical School and the Broad Institute, and Nicole Paulk, Ph.D., of the University of California San Francisco

References

Golden logo
By using this site, you agree to our Terms & Conditions.